BEAM

BEAM: BiCNU, Etoposide, Ara-C, Melphalan

Regimen (Jo, et al. 2008)

Autologous blood stem cells are infused on day 0.

• Carmustine (BiCNU) 300 mg/m2 IV on day -6
• Etoposide (Vepesid) 200 mg/m2 IV on days -5 to -2
• Cytarabine (Cytosar) 400 mg/m2 IV on days -5 to -2
• Melphalan (Alkeran) 140 mg/m2 IV on day -1

Supportive medications:

• Filgrastim (Neupogen) 5 mcg/kg SC daily starting on day +1, continued until there are 3 consecutive days with ANC ≥1000
• Prophylaxis against opportunistic infections and management of febrile neutropenia per "active protocols"

Alternate regimen #1 (Stewart, et al. 2006)

Autologous blood stem cells are infused on day 0.

• Carmustine (BiCNU) 300 mg/m2 IV on day -6
• Etoposide (Vepesid) 100 mg/m2 IV Q12H on days -5 to -2 (8 total doses)
• Cytarabine (Cytosar) 200 mg/m2 IV Q12H on days -5 to -2 (8 total doses)
• Melphalan (Alkeran) 140 mg/m2 IV on day -1

Supportive medications:

• Patients <70 kg: Filgrastim (Neupogen) 300 mcg SC daily starting on day +7 after stem cell transplant
• Patients >70 kg (reference did not clarify which dosage to use for patients who are exactly 70 kg): Filgrastim (Neupogen) 480 mcg SC daily starting on day +7 after stem cell transplant
• Trimethoprim/Sulfamethoxazole (Bactrim DS) (160/800 mg) PO BID on Monday and Thursdays, until 6 months after BEAM

While ANC <500

• Ciprofloxacin (Cipro) 500 mg PO BID
• Fluconazole (Diflucan) 100 mg PO daily or mycostatin 500,000 units swish & swallow QID
• Acyclovir (Zovirax) 400 mg PO TID

Alternate regimen #2 (Josting, et al. 2005)

Paper did not specify which day peripheral blood stem cells were administered.

• Carmustine (BiCNU) 300 mg/m2 IV on day 1
• Etoposide (Vepesid) 150 mg/m2 IV Q12H on days 2-5 (8 total doses)
• Cytarabine (Cytosar) 200 mg/m2 IV Q12H on days 2-5 (8 total doses)
• Melphalan (Alkeran) 140 mg/m2 IV on day 1

References

1. Josting A, Sieniawski M, Glossmann JP, Staak O, Nogova L, Peters N, Mapara M, Dörken B, Ko Y, Metzner B, Kisro J, Diehl V, Engert A. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. Ann Oncol. 2005 Aug;16(8):1359-65. Epub 2005 Jun 6. link to original article contains protocol PubMed
2. Stewart DA, Bahlis N, Valentine K, Balogh A, Savoie L, Morris DG, Jones A, Brown C, Russell JA. Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2006 Jun 15;107(12):4623-7. Epub 2006 Feb 7. link to original article contains protocol PubMed
3. Jo JC, Kang BW, Jang G, Sym SJ, Lee SS, Koo JE, Kim JW, Kim S, Huh J, Suh C. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity. Ann Hematol. 2008 Jan;87(1):43-8. Epub 2007 Aug 21. link to original article contains protocol PubMed

References

1. Przepiorka D, van Besien K, Khouri I, Hagemeister F, Samuels B, Folloder J, Ueno NT, Molldrem J, Mehra R, Körbling M, Giralt S, Gajewski J, Donato M, Cleary K, Claxton D, Braunschweig I, Andersson B, Anderlini P, Champlin R. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol. 1999 May;10(5):527-32. link to original article contains protocol PubMed